0.761 USD
+0.01 (+1.55%)
0.7641 USD
+0 (+0.41%)
Taking everything into account, HBIO scores 3 out of 10 in our fundamental rating. HBIO was compared to 58 industry peers in the Life Sciences Tools & Services industry. HBIO may be in some trouble as it scores bad on both profitability and health. HBIO is cheap, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
HBIO had positive earnings in the past year.
In the past year HBIO had a positive cash flow from operations.
HBIO had negative earnings in each of the past 5 years.
Each year in the past 5 years HBIO had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of -69.03%, HBIO is not doing good in the industry: 87.93% of the companies in the same industry are doing better.
HBIO's Return On Equity of -382.68% is on the low side compared to the rest of the industry. HBIO is outperformed by 87.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.03% | ||
| ROE | -382.68% | ||
| ROIC | N/A |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 56.94%, HBIO is doing good in the industry, outperforming 74.14% of the companies in the same industry.
In the last couple of years the Gross Margin of HBIO has remained more or less at the same level.
HBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
2. Health
2.1 Basic Checks
HBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HBIO has been increased compared to 1 year ago.
The number of shares outstanding for HBIO has been increased compared to 5 years ago.
HBIO has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -2.61, we must say that HBIO is in the distress zone and has some risk of bankruptcy.
HBIO's Altman-Z score of -2.61 is on the low side compared to the rest of the industry. HBIO is outperformed by 82.76% of its industry peers.
HBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 4.98 | ||
| Altman-Z | -2.61 |
ROIC/WACCN/A
WACC10.95%
2.3 Liquidity
HBIO has a Current Ratio of 0.81. This is a bad value and indicates that HBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
HBIO has a worse Current ratio (0.81) than 93.10% of its industry peers.
A Quick Ratio of 0.41 indicates that HBIO may have some problems paying its short term obligations.
HBIO has a worse Quick ratio (0.41) than 96.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 |
3. Growth
3.1 Past
The earnings per share for HBIO have decreased by 0.00% in the last year.
The earnings per share for HBIO have been decreasing by -19.73% on average. This is quite bad
HBIO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -10.60%.
Measured over the past years, HBIO shows a decrease in Revenue. The Revenue has been decreasing by -4.12% on average per year.
EPS 1Y (TTM)0%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%100%
Revenue 1Y (TTM)-10.6%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-6.28%
3.2 Future
The Earnings Per Share is expected to grow by 45.77% on average over the next years. This is a very strong growth
HBIO is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.21% yearly.
EPS Next Y-57.5%
EPS Next 2Y45.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.8%
Revenue Next 2Y-1.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
HBIO is valuated rather expensively with a Price/Earnings ratio of 19.02.
Based on the Price/Earnings ratio, HBIO is valued cheaply inside the industry as 91.38% of the companies are valued more expensively.
HBIO is valuated rather cheaply when we compare the Price/Earnings ratio to 26.31, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 5.97, the valuation of HBIO can be described as very cheap.
100.00% of the companies in the same industry are more expensive than HBIO, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.59, HBIO is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.02 | ||
| Fwd PE | 5.97 |
4.2 Price Multiples
94.83% of the companies in the same industry are more expensive than HBIO, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HBIO indicates a rather cheap valuation: HBIO is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.97 | ||
| EV/EBITDA | 13.71 |
4.3 Compensation for Growth
HBIO's earnings are expected to grow with 45.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.77%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for HBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.761
+0.01 (+1.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners58.21%
Inst Owner Change-12.33%
Ins Owners3.72%
Ins Owner Change9.91%
Market Cap33.89M
Revenue(TTM)87.37M
Net Income(TTM)-53.84M
Analysts80
Price Target2.04 (168.07%)
Short Float %17.68%
Short Ratio0.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-49.02%
Min EPS beat(2)-100%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)-1.23%
Min EPS beat(4)-100%
Max EPS beat(4)75.49%
EPS beat(8)3
Avg EPS beat(8)-39.49%
EPS beat(12)5
Avg EPS beat(12)-32.85%
EPS beat(16)5
Avg EPS beat(16)-35.95%
Revenue beat(2)1
Avg Revenue beat(2)-0.39%
Min Revenue beat(2)-1.72%
Max Revenue beat(2)0.94%
Revenue beat(4)2
Avg Revenue beat(4)2.52%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)11.18%
Revenue beat(8)2
Avg Revenue beat(8)-3.88%
Revenue beat(12)3
Avg Revenue beat(12)-4.45%
Revenue beat(16)3
Avg Revenue beat(16)-4.48%
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)-12.5%
EPS NQ rev (3m)-22.22%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.91%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.02 | ||
| Fwd PE | 5.97 | ||
| P/S | 0.39 | ||
| P/FCF | 4.97 | ||
| P/OCF | 3.96 | ||
| P/B | 2.41 | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.71 |
EPS(TTM)0.04
EY5.26%
EPS(NY)0.13
Fwd EY16.75%
FCF(TTM)0.15
FCFY20.13%
OCF(TTM)0.19
OCFY25.23%
SpS1.96
BVpS0.32
TBVpS-0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.53
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.03% | ||
| ROE | -382.68% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.94% | ||
| FCFM | 7.81% |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
F-Score4
Asset Turnover1.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 4.98 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 27.22% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 193.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 | ||
| Altman-Z | -2.61 |
F-Score4
WACC10.95%
ROIC/WACCN/A
Cap/Depr(3y)33.21%
Cap/Depr(5y)26.48%
Cap/Sales(3y)2.31%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%100%
EPS Next Y-57.5%
EPS Next 2Y45.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-10.6%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-6.28%
Revenue Next Year-8.8%
Revenue Next 2Y-1.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y63.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4466.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.1%
OCF growth 3Y4.55%
OCF growth 5Y-29.12%
HARVARD BIOSCIENCE INC / HBIO FAQ
What is the ChartMill fundamental rating of HARVARD BIOSCIENCE INC (HBIO) stock?
ChartMill assigns a fundamental rating of 3 / 10 to HBIO.
What is the valuation status of HARVARD BIOSCIENCE INC (HBIO) stock?
ChartMill assigns a valuation rating of 7 / 10 to HARVARD BIOSCIENCE INC (HBIO). This can be considered as Undervalued.
Can you provide the profitability details for HARVARD BIOSCIENCE INC?
HARVARD BIOSCIENCE INC (HBIO) has a profitability rating of 2 / 10.
What is the expected EPS growth for HARVARD BIOSCIENCE INC (HBIO) stock?
The Earnings per Share (EPS) of HARVARD BIOSCIENCE INC (HBIO) is expected to decline by -57.5% in the next year.